Clinical Specialties is voluntarily recalling Avastin unit dose syringes. The product has or potentially could result in an infection within the eye. Clinical Specialties has received reports of five intraocular infections from physician’s offices and this is how the problem was identified.

Three studies released today present possible positive news for people with Parkinson’s disease.

If you ask most people if having a partial paralysis would hinder you from pursuing sports, the answer might be yes.  But they might think twice if they met 16-year-old Joe Cancilla of Walled Lake, MI.

Celgene International Sàrl presented the results from ESTEEM 1, the Company’s first phase III study in psoriasis, at the American Academy of Dermatology annual meeting in Miami, Florida.

The US Food and Drug Administration (FDA) has approved ABILIFY MAINTENA™ (aripiprazole) for extended release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

Affymax, Inc. and Takeda Pharmaceutical Company Limited today have decided to voluntarily recall all lots of OMONTYS® (peginesatide) Injection to the user level as a result of new post-marketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life threatening or fatal.

Smithfield Packing Company, a Smithfield, VA, establishment, is recalling approximately 38,000 pounds of pork sausage that may contain small pieces of plastic, likely from gloves, the US Department of Agriculture's Food Safety and Inspection Service (FSIS) announced today.

Peregrine Pharmaceuticals announced results from its 70 patient open-label, randomized Phase II clinical trial of bavituximab used in combination with gemcitabine in patients with previously untreated, advanced Stage IV pancreatic cancer.

Sudden cardiac arrest, when the heart suddenly becomes unable to function properly, occurs in several hundred thousand individuals in the United States yearly.

Eli Lilly and Company announced today that it will discontinue the Phase 3 rheumatoid arthritis (RA) program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, due to lack of efficacy.